Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab

被引：2
|
作者：
Hiraga, Junji [1 ]
Tomita, Akihiro [2 ]
Suzuki, Naruko [1 ]
Takagi, Yusuke [1 ]
Narita, Michihiko [3 ]
Kagami, Yoshitoyo [1 ]
机构：
[1] Toyota Kosei Hosp, Dept Hematol, 500-1 Ibobara,Josui Cho, Toyota 4700396, Japan
[2] Fujita Hlth Univ, Sch Med, Dept Hematol, Toyoake, Aichi, Japan
[3] Toyota Kosei Hosp, Dept Pathol, Toyota, Japan
来源：
ANNALS OF HEMATOLOGY | 2018年 / 97卷 / 11期
关键词：
CHEMOTHERAPY PLUS RITUXIMAB; CHOP;
D O I：
10.1007/s00277-018-3354-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2253 / 2255
页数：3
相关论文
共 50 条
  • [1] Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab
    Junji Hiraga
    Akihiro Tomita
    Naruko Suzuki
    Yusuke Takagi
    Michihiko Narita
    Yoshitoyo Kagami
    Annals of Hematology, 2018, 97 : 2253 - 2255
  • [2] Restoration of rituximab sensitivity in CD20 negative B-Cell lymphoma, cells; Epigenetic change of CD20 expression after treatment of rituximab.
    Tomita, Akihiro
    Hiraga, Junji
    Kiyoi, Hitoshi
    Kinoshita, Tomohiro
    Naoe, Tornoki
    BLOOD, 2006, 108 (11) : 155B - 155B
  • [3] CD20-negative relapse in B-cell lymphoma after treatment with Rituximab
    Kinoshita, T
    Nagai, H
    Murate, T
    Saito, H
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) : 3916 - 3916
  • [4] CD20-Negative Phenotypic Change In B-Cell Lymphoma Cells After Using Rituximab: Possibility of a Particular Clinicopathologic Phenomenon Post-Rituximab Extranodal CD20-Negative Lymphoma
    Tomita, Akihiro
    Tokunaga, Takashi
    Iriyarna, Chisako
    Shimada, Kazuyuki
    Hiraga, Junji
    Sugimoto, Takumi
    Kiyoi, Hitoshi
    Nakamura, Shigeo
    Kinoshita, Tortiohiro
    Naoe, Tomoki
    BLOOD, 2010, 116 (21) : 1184 - 1184
  • [5] CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma
    Nakamaki, Tsuyoshi
    Fukuchi, Kunihiko
    Nakashima, Hidetoshi
    Ariizumi, Hirotsugu
    Maeda, Takashi
    Saito, Bungo
    Yanagisawa, Kouji
    Tomoyasu, Shigeru
    Homma, Mayumi
    Shiozawa, Eisuke
    Yamochi-Onizuka, Toshiko
    Ota, Hidekazu
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 89 (04) : 350 - 355
  • [6] Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): A case report and review of the literature
    Duman, Berna Bozkurt
    Sahin, Berksoy
    Ergin, Melek
    Guvenc, Birol
    MEDICAL ONCOLOGY, 2012, 29 (02) : 1223 - 1226
  • [7] Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): A case report and review of the literature
    Berna Bozkurt Duman
    Berksoy Şahin
    Melek Ergin
    Birol Guvenc
    Medical Oncology, 2012, 29 : 1223 - 1226
  • [8] MS4A1 (CD20) Gene Expression is Down-Regulated by Recruiting the Histone Deacetylase Protein Complex to the Promoter in the CD20-Negative B-Lymphoma Cells After Treatment with Rituximab
    Sugimoto, Takumi
    Tomita, Akihiro
    Hiraga, Junji
    Shimada, Kazuyuki
    Kiyoi, Hitoshi
    Kinoshita, Tomohiro
    Naoe, Tomoki
    BLOOD, 2009, 114 (22) : 527 - 527
  • [9] Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy
    Clarke, LE
    Bayerl, MG
    Ehmann, WC
    Helm, KF
    JOURNAL OF CUTANEOUS PATHOLOGY, 2003, 30 (07) : 459 - 462
  • [10] Unclassifiable CD20-negative Testicular Diffuse Large B-cell Lymphoma
    Garrido-Abad, Pablo
    Garcia-Martin, Luis
    Villar-Zarra, Karen
    Diaz-Menendez, Ariel
    Fernandez-Arjona, Manuel
    UROLOGY, 2018, 117 : E3 - E4
12345